Value of public health interventions for HIV, HBV and HCV integrated screening: The FOCUS-CRIVALVIR programme.

INTRODUCTION A late diagnosis of human immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis B virus (HBV) increases the chances of transmission and healthcare costs, as well as increases morbidity and the progression of the disease. The objective is to evaluate the impact of FOCUS-CRIVALVIR programme implementation on the transmission of these viruses and the costs in the Valencian Community (3,902,512 adults) compared with nonimplementation. METHODS A decision tree is developed to estimate the number of individuals screened and their follow-up in healthcare, combined with a transmission model for each virus to evaluate infections and mortality avoided and costs of new infections and late diagnosis. The analysis is carried out in different at-risk populations. The population susceptible to infection, interactions between individuals and the risk of transmission among undiagnosed individuals, untreated and treated without a response are considered. RESULTS With FOCUS-CRIVALVIR programme, 440,203 individuals would be screened; 1064-HIV, 1455-HCV and 1627-HBV infections would be diagnosed; and 1053, 1422 and 111 individuals would be treated, respectively. Compared with nonintervention, FOCUS-CRIVALVIR programme would avoid 464 new HIV, 524 new HCV and 169 new HBV infections within 20 years and reduce mortality. The programme would cost 6 million euros (€M) to implement but would save € 154M (€ 152M infections avoided and € 8M late diagnosis less cost programme) vs nonintervention. CONCLUSIONS The implementation of the FOCUS-CRIVALVIR programme would enable early access to the diagnosis and treatment of HIV, HCV and HBV; reduce the transmission, mortality, and costs of new infections and late diagnosis; and add value to society and the healthcare system.

• Publication year

  2025

• Venue

  Annals of Epidemiology

• Publication date

  2025-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.annepidem.2025.06.014PMID 40588193
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Universal screening and treatment towards the elimination of chronic hepatitis C in China: an economic evaluation.

  2024cited by this paper
• Combined “Test and Treat” Campaigns for Human Immunodeficiency Virus, Hepatitis B, and Hepatitis C: A Systematic Review to Provide Evidence to Support World Health Organization Treatment Guidelines

  2024cited by this paper
• Opportunistic population screening as a hepatitis elimination strategy: The CRIVALVIR-FOCUS program.

  2024cited by this paper
• Hepatitis C Virus Infection in the Elderly in the Era of Direct-Acting Antivirals: Evidence from Clinical Trials and Real Life

  2023cited by this paper
• Hepatitis C antibody prevalence and active hepatitis C infection in HIV-negative gay, bisexual, and other men who have sex with men in Barcelona and Madrid, Spain (March 2018-March 2021)

  2023cited by this paper
• Estimates of hepatitis B virus prevalence among general population and key risk groups in EU/EEA/UK countries: a systematic review

  2023cited by this paper
• The Efficiency of Increased HCV Testing and Treatment Strategies in Spain to Achieve Elimination Goals

  2023cited by this paper
• Updates on Hepatitis B Virus (HBV) Infection 2.0

  2023cited by this paper
• The economic burden of HIV-associated wasting in the era of modern antiretroviral therapy.

  2022cited by this paper
• Clinical and economic value of sofosbuvir-based regimens in the treatment of chronic hepatitis C in Spain

  2022cited by this paper
• The effect of hepatitis C—associated premature deaths on labour productivity losses in Spain: a ten-year analysis

  2022cited by this paper
• Achieving the UNAIDS goals by 2030 in people living with HIV: A simulation model to support the prioritization of health care interventions.

  2022cited by this paper
• Considerations for transferability of health technology assessments: a scoping review of tools, methods, and practices

  2022cited by this paper
• Recommendations for the integral diagnosis of chronic viral hepatitis in a single analytical extraction.

  2022cited by this paper
• HIV screening and linkage to care in a health department in Valencia, Spain: Lessons learned from a healthcare quality improvement project

  2022cited by this paper
• Epidemiologic and Economic Analysis of Rapid Antiretroviral Therapy Initiation with Bictegravir/Emtricitabine/Tenofovir Alafenamide in Spain

  2022cited by this paper
• Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study.

  2021cited by this paper
• Implementation of pre-exposure prophylaxis programme in Spain. Feasibility of four different delivery models

  2021cited by this paper
• Clinical and economic benefit of 32 years of antiretroviral treatment for people living with HIV in Spain: Has it been an efficient intervention?

  2021cited by this paper
• Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry review

  2021cited by this paper
• Clinical and economic impact of an alert system in primary care for the detection of patients with chronic hepatitis C

  2021cited by this paper
• Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020).

  2020cited by this paper
• Mortality in adults with chronic hepatitis B infection in the United States: a population‐based study

  2020cited by this paper
• Efficacy and safety of direct‐acting antivirals for hepatitis C in the elderly: A systematic review and meta‐analysis

  2019cited by this paper
• Reinfection by HCV following effective all-oral DAA therapy in HIV/HCV-coinfected individuals.

  2019cited by this paper
• Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection

  2019cited by this paper
• Can we afford to offer pre-exposure prophylaxis to MSM in Catalonia? Cost-effectiveness analysis and budget impact assessment

  2018cited by this paper
• Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

  2018cited by this paper
• Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in Europe

  2018cited by this paper
• Healthcare and economic impact.

  2018cited by this paper
• Economic and epidemiologic impact of guidelines for early ART initiation irrespective of CD4 count in Spain

  2018cited by this paper
• Cost-effectiveness analysis of two treatment strategies for chronic hepatitis C before and after access to direct-acting antivirals in Spain.

  2017cited by this paper
• Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial

  2016cited by this paper
• Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH‐C) patients: an economic model from five European countries

  2016cited by this paper
• Hepatitis C virus infection and its relationship to certain sexual practices in men-who-have-sex-with-men in Spain: results from the European MSM internet survey (EMIS).

  2015cited by this paper
• On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.

  2015cited by this paper
• Expansion of HAART Coverage Is Associated with Sustained Decreases in HIV/AIDS Morbidity, Mortality and HIV Transmission: The “HIV Treatment as Prevention” Experience in a Canadian Setting

  2014cited by this paper
• The Economic Burden of Late Entry Into Medical Care for Patients With HIV Infection

  2010cited by this paper
• Decreases in Community Viral Load Are Accompanied by Reductions in New HIV Infections in San Francisco

  2010cited by this paper
• Natural history of hepatitis B virus infection: an update for clinicians.

  2007cited by this paper

• No citing papers are available for this paper.